Scope and Claims Analysis of US Patent 9,169,307 (Complement Inhibitory Disulfide-Bridged Peptides) and the U.S. Patent Landscape
US 9,169,307 protects a tightly defined class of C3-targeting complement activation inhibitors built around a disulfide-cyclized peptide scaffold with a specified 11-aa core sequence (SEQ ID NO: 26) and broad substitution logic at five variable positions (Xaa1, Xaa2, Xaa3, Xaa4, Xaa5). Independent claim 1 covers the compound; claims 13-15 cover making; claims 16-19 cover use/methods including therapeutic and ex vivo applications; claim 10 extends coverage to PEGylated versions; claims 11-12 extend coverage to albumin-binding retention formats.
What does US 9,169,307 claim protect: the exact peptide scaffold, variable residues, and core binding concept?
Short answer: The patent claims disulfide-bonded peptides that inhibit complement activation by binding/interaction with C3, using a fixed “Cys–Val–Gln–Asp–Gly–His–Arg–Cys” framework and five substitution positions that define the allowed chemical space.
What is the claimed structure?
Core sequence (SEQ ID NO: 26):
Xaa1–Cys–Val–Xaa2–Gln–Asp–Xaa3–Gly–Xaa4–His–Arg–Cys–Xaa5
with the two cysteines joined by a disulfide bond (intramolecular disulfide).
This is a constrained cyclic peptide conceptually aligned with a “C3-interaction epitope” rather than an unconstrained linear motif, because the disulfide requirement is express.
Which parts are fixed vs variable?
Fixed positions in the scaffold (not varied by the claim language):
- Cys (position 2 and penultimate position 12)
- Val
- Gln
- Asp
- Gly
- His
- Arg
Variable positions (Xaa1, Xaa2, Xaa3, Xaa4, Xaa5) drive both binding and pharmacokinetic/performance coverage.
Allowed residue substitutions and how they map to function
Xaa1 (N-terminal “start” residue set):
- Ile, Val, Leu, or acetylated forms (Ac-Ile/Ac-Val/Ac-Leu)
- or a dipeptide comprising Gly–Ile
This is a claim expansion for common protective-group or N-cap equivalents, plus a specific dipeptide cap option.
Xaa2 (Trp analog set, hydrophobic interaction with C3):
- Trp
- or an analog with increased hydrophobic character vs Trp
- plus explicit “if Xaa3 is Trp then Xaa2 must be…” proviso defining narrower alternatives:
- includes 5-fluoro-L-tryptophan or 6-fluoro-L-tryptophan
- or lower alkoxy or lower alkyl substituents at position 1 or 5
- or lower alkanoyl at position 1
Xaa3 (Trp or indole modification increasing H-bond potential):
- Trp
- or an analog with chemical modification to indole ring that increases hydrogen bond potential.
- Explicitly, if Xaa3 is Trp, the claim engages the proviso above (tightening Xaa2 choices).
Xaa4 (position adjacent to His/Arg cluster):
- His, Ala, Phe, or Trp
Claim 7 nails down a narrower sub-scope: Xaa4 = Ala.
Xaa5 (C-terminus residue/cap set, with optional amide conversion):
- L-Thr, D-Thr, Ile, Val, Gly
- or dipeptide: Thr–Asn or Thr–Ala
- or tripeptide: Thr–Ala–Asn
- and the terminal —OH optionally replaced by —NH2 (amide substitution), including for residues Asn/Thr and also when that position is embodied in the peptide end.
What do claims 2–9 add beyond claim 1?
Claims 2–9 are subordinate narrowing or functional-constraint clauses that do two things:
- define acceptable binding interaction patterns with C3 (nonpolar vs hydrogen bond), and
- lock additional specific tryptophan substitutions.
Claim 2 adds conditional binding language:
- (a) Xaa2 participates in nonpolar interaction with C3
- (b) Xaa3 participates in hydrogen bond with C3
- (c) both
This matters because it supports an argument that the claimed analogs share a binding mode rather than just “sequence-only” coverage.
Claim 3: Xaa2 is 5-methoxytryptophan or 5-methyltryptophan.
Claim 4: Xaa2 is 1-methyltryptophan or 1-formyltryptophan.
Claim 5–6: Xaa3 can be halogenated tryptophan, specifically 5-fluoro-L-Trp or 6-fluoro-L-Trp.
Claim 8–9: adds combined specific scenarios:
- Xaa2 includes lower alkanoyl or lower alkyl at 1
- Xaa3 optionally halogenated
- Xaa4 = Ala
- then further narrows: Xaa2 = 1-methyltryptophan or 1-formyltryptophan and Xaa3 optionally = 5-fluoro-L-Trp.
The “PEGylated” and “retention peptide” extensions
Claim 10: “compound is PEGylated.”
This creates a broad format extension, not a specific PEG size or attachment chemistry is stated in the claim text you provided, so PEGylation is covered generically.
Claims 11–12: “additional peptide component that extends in vivo retention,” including an albumin binding peptide.
This expands the covered “drug product” universe beyond the disulfide core to include retention motifs (albumin tethering).
How broad is the claim scope: does US 9,169,307 read on peptidomimetics, PEG forms, and analog libraries?
Short answer: It is broad on substitutions and drug formats (PEGylation, albumin-binding retention components) but narrow on the sequence and disulfide constraint. It also includes method claim 19 that explicitly connects to peptide analog/peptidomimetic design and screening.
What is broad vs narrow
Broad aspects
-
Xaa2 and Xaa3 accept “analogs” under functional criteria:
- Xaa2: increased hydrophobicity vs Trp, plus defined specific substituent categories
- Xaa3: increased hydrogen bond potential
-
Xaa1 includes acetylated versions and a dipeptide “Gly–Ile” option.
-
Xaa5 includes multiple residue or short peptide options and allows terminal conversion of terminal hydroxyl to amide (—NH2).
-
Drug product formats:
- PEGylated (claim 10)
- additional peptide retention component, including albumin-binding peptides (claims 11–12)
Narrow aspects
- The disulfide bond between the two cysteines is explicit and structural.
- The backbone contains fixed residues at multiple positions (Val, Gln, Asp, Gly, His, Arg).
- The overall scaffold length and positional identity are anchored by the stated sequence format.
Does it cover “peptidomimetics” explicitly?
Claim 19 references design of peptide analogs and peptidomimetics and screening for compounds that inhibit complement activation or compete for binding to C3/C3 fragments. This is not the same as a direct claim to any peptidomimetic structure, but it does:
- create a functional method hook for discovery screens and design workflows, and
- tie the patent’s technical narrative to C3 competitive binding.
Practically, infringement risk for peptidomimetics will hinge on whether those peptidomimetics satisfy claim 1’s compound definition (sequence + disulfide bond), or whether a party’s activity could be captured under method claims 19.
What patents protect complement inhibitors targeting C3 with disulfide-cyclized tryptophan/indole variants?
Short answer: With only the text provided for US 9,169,307, a complete cross-patent mapping cannot be produced. The patent’s claim language itself indicates the main protected concept: a C3-interacting, disulfide-cyclized peptide with Trp/Trp-analog substitution that adjusts hydrophobic and hydrogen-bonding contributions.
Inference from the claim itself (what to look for in other patents)
Competitor or blocking estates in this space typically cluster around:
- C3 inhibitors (peptides, engineered proteins, small molecules)
- C3-binding motifs with tryptophan-based hydrophobic pockets
- cyclic/disulfide constrained peptides
- PEGylation and albumin-binding retention extensions
- therapeutic use claims for complement-driven tissue injury
- ex vivo complement inhibition in extracorporeal circulation and artificial organs
Your claim 2 language (“nonpolar interaction with C3” and “hydrogen bond with C3”) is a clue that other patents in the family or related claims often emphasize interaction mode rather than only sequence.
What is the invention’s functional mechanism: how do Xaa2/Xaa3 substitutions map to C3 binding?
Short answer: The patent builds a structure-function rationale: Xaa2 drives hydrophobic interactions with C3, while Xaa3 drives hydrogen bonding with C3, using tryptophan or indole-modified tryptophans.
Claims 1 and 2 together define “interaction mode” coverage
- Claim 1 defines chemistry space (allowed tryptophan analogs and indole ring modifications).
- Claim 2 explicitly ties interaction roles:
- Xaa2 nonpolar with C3
- Xaa3 hydrogen bond with C3
This framing affects interpretation during claim construction:
- The “increased hydrophobic character” qualifier for Xaa2 is consistent with nonpolar packing.
- The “increased hydrogen bond potential” qualifier for indole modifications is consistent with hydrogen bonding.
How strong is the patent estate for US 9,169,307: what claim features create resilience or vulnerability?
Short answer: Strength is driven by (1) structural specificity (disulfide-cyclized scaffold), and (2) functional constraints (hydrophobic vs H-bond contributions to C3), with format breadth (PEGylation and albumin retention) increasing coverage. Vulnerability is mainly around potential overlap with known complement C3-binding peptides and generic use claims for complement inhibition.
Resilience factors
- Disulfide bond requirement narrows the field versus linear peptides.
- Defined variable residue sets reduce claim “free-form” breadth, which can help novelty/nonobviousness arguments.
- Explicit PEGylation and albumin-binding extensions broaden “in-product” coverage.
Possible vulnerability vectors (doctrinal, not speculative)
- “Analog” language (Xaa2 hydrophobicity; Xaa3 hydrogen bond potential) can be litigated over whether design-arounds still fit “increased” character thresholds.
- Claim 19 method language can be attacked as overly broad if construed to cover routine screening steps without additional patentable technical limitations.
What manufacturing and process steps are protected: does US 9,169,307 cover synthesis and PEGylation steps?
Short answer: Claims 13–15 explicitly cover both (a) peptide synthesis by condensation or recombinant expression and (b) specific post-synthesis modifications including disulfide cyclization, acetylation, terminal hydroxyl to amide conversion, PEGylation, and adding retention peptides.
Claim 13 scope (process definition)
- Method of making the compound comprises synthesizing the peptide by:
- condensation of amino acid residues/analogs, or
- expressing a polynucleotide encoding the peptide
This covers both chemical peptide synthesis and recombinant expression strategies.
Claim 14 adds cyclization
- Further comprising cyclizing through formation of a disulfide bond between the two Cys residues.
Claim 15 adds post-synthesis modification set
Protected post-synthesis modifications include:
- (a) acetylation of Xaa1
- (b) replacing terminal —OH of Xaa4 with —NH2
- (3) PEGylation
- (4) synthesizing with an additional retention peptide component
This is a direct litigation lever for:
- CMO contract processes performing these modifications, and
- formulation/manufacturing descriptions that align with the claim list.
What therapeutic and ex vivo uses are claimed: blood/serum, artificial organs, and extracorporeal shunting?
Short answer: Claims 16–18 cover contacting a medium with the inhibitor in settings including blood/serum, artificial organs/implants, extracorporeal shunting fluids, and treatment of diseases where complement contributes to tissue damage.
Claim 16: broad “contacting the medium”
- contacting the medium where complement activation occurs
- by using the specific peptide inhibitor definition
Claim 17: specific environments
Inhibition is claimed for:
- blood or serum
- artificial organs or implants
- physiological fluids during extracorporeal shunting
Claim 18: disease and condition treatment hook
- complement inhibition “as part of a treatment” for diseases where complement activation contributes to cell damage or tissue injury
This supports broad therapeutic use without needing a particular indication in the claim text you provided.
How does US 9,169,307 relate to complement activation competitive binding to C3 fragments?
Short answer: Claim 19 frames screening/design around compounds that inhibit complement activation or compete for binding to C3 or a C3 fragment.
Claim 19 scope
- adapted to:
- design peptide analogs or peptidomimetics, or
- screen a small molecule library
- identify compounds that:
- inhibit complement activation or
- compete with the complement inhibitor for binding to C3 or C3 fragments
This matters for licensing and noninfringement arguments because it defines the competitive-binding axis around the inhibitor.
What generic entry risks exist for products built on this disulfide-cyclized C3 inhibitor peptide?
Short answer: If the commercial product is a fixed peptide sequence analog within claim 1’s envelope (including PEGylation and retention-peptide variants), “generic entry” risk maps to (1) whether the competitor matches the disulfide-cyclized scaffold and the allowed residue sets, and (2) whether drug product format (PEGylation/albumin tethering) is captured.
Design-around logic competitors will evaluate
- Alter disulfide formation requirement (replace Cys pair or prevent disulfide cyclization).
- Shift fixed residues (Val/Gln/Asp/Gly/His/Arg) if outside structural equivalents.
- Use alternative aromatic residues instead of Trp/indole analogs at Xaa2/Xaa3, or modify tryptophan in ways that do not meet “increased hydrophobic character” or “increased hydrogen bond potential” thresholds as construed.
- Change C-terminus cap logic such that it falls outside Xaa5’s residue/dipeptide/tripeptide sets.
Key Takeaways
- US 9,169,307 is anchored on a disulfide-bonded cyclic peptide scaffold with fixed core residues and five defined variable positions.
- Claims 1–9 protect C3-interacting peptide variants where Xaa2 governs hydrophobic interactions and Xaa3 governs hydrogen bonding, using Trp or indole-modified tryptophan analogs.
- Claims 10–12 broaden product coverage to PEGylated and albumin-binding retention formats.
- Claims 13–15 protect key manufacturing and post-synthesis steps, including cyclization via disulfide formation and PEGylation and retention-peptide addition.
- Claims 16–18 cover therapeutic and ex vivo complement inhibition across blood/serum, artificial organs/implants, and extracorporeal shunting fluids.
- Claim 19 extends the concept into screening and design for competitive inhibitors targeting C3 or C3 fragments.
FAQs
1) Does US 9,169,307 cover both L- and D-amino acids?
Yes for Xaa5, which explicitly includes D-Thr among allowed options, and generally includes “analogs” in Xaa1–Xaa3 variable definitions.
2) Are PEGylation attachment sites or PEG chain lengths limited in the claims you provided?
No limits are stated in the claim text provided for claim 10; it requires only that the compound is PEGylated.
3) Is albumin binding peptide coverage limited to a named sequence?
No specific albumin-binding peptide sequence is provided in the claim text you supplied; claim 12 requires an albumin binding peptide as the retention component.
4) Can a competitor infringe by using a peptide that has cysteines but not disulfide cyclization?
Claim 1 explicitly requires that “the two Cys residues are joined by a disulfide bond,” so avoiding disulfide cyclization is the core design-around axis.
5) Does the patent cover methods limited to a particular disease indication?
No. Claim 18 is framed broadly as treating diseases/conditions where complement activation contributes to cell damage or tissue injury.
References
- United States Patent US 9,169,307.
